India, Jan. 22 -- Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced its consolidated financial results for the fiscal third quarter ended December 31, 2020.

Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, "Consolidated revenue forQ3FY21increased 7 per cent year on year to Rs 1,879 crore driven by 13 per cent growth inResearch Services, and 11 per cent inBiosimilarbusiness segments.EBITDA for the quarter stood at Rs 427 croreandnet profitwas at Rs 169 crore. OurCore EBITDA marginsstood at 31 per cent.

"The two recent investments of $225 million in Biocon Biologics byGoldman SachsandADQ endorse the value creation of our biosimilars business. These investments augur well for...